Royal Bank Of Canada reaffirmed their hold rating on shares of Baxter International Inc. (NYSE:BAX) in a research note issued to investors on Wednesday morning. They currently have a $66.00 price target on the medical instruments supplier’s stock.

Other equities research analysts have also issued reports about the stock. BMO Capital Markets restated a buy rating and set a $70.00 target price on shares of Baxter International in a research report on Friday, October 13th. Zacks Investment Research upgraded shares of Baxter International from a hold rating to a buy rating and set a $69.00 target price on the stock in a research report on Tuesday, October 10th. Cantor Fitzgerald set a $70.00 target price on shares of Baxter International and gave the stock a buy rating in a research report on Wednesday, July 26th. BidaskClub lowered shares of Baxter International from a strong-buy rating to a buy rating in a research report on Monday, July 31st. Finally, Morgan Stanley boosted their target price on shares of Baxter International from $59.00 to $62.00 and gave the stock an equal weight rating in a research report on Thursday, October 26th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $67.46.

Shares of Baxter International (NYSE BAX) opened at $64.12 on Wednesday. The company has a market cap of $34,891.03, a price-to-earnings ratio of 26.46, a price-to-earnings-growth ratio of 2.14 and a beta of 0.68. Baxter International has a 1 year low of $43.13 and a 1 year high of $65.70. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.22 and a current ratio of 2.80.

Baxter International (NYSE:BAX) last issued its earnings results on Wednesday, October 25th. The medical instruments supplier reported $0.64 EPS for the quarter, topping the consensus estimate of $0.59 by $0.05. The company had revenue of $2.71 billion for the quarter, compared to analyst estimates of $2.66 billion. Baxter International had a net margin of 9.88% and a return on equity of 15.00%. The business’s revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.56 EPS. sell-side analysts predict that Baxter International will post 2.43 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, January 2nd. Investors of record on Friday, December 1st will be given a $0.16 dividend. The ex-dividend date is Thursday, November 30th. This represents a $0.64 annualized dividend and a dividend yield of 1.00%. Baxter International’s dividend payout ratio is presently 34.41%.

In related news, Director Third Point Llc sold 5,000,000 shares of the business’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $64.23, for a total value of $321,150,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Thomas T. Stallkamp sold 8,920 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $62.28, for a total transaction of $555,537.60. Following the completion of the sale, the director now owns 16,263 shares in the company, valued at $1,012,859.64. The disclosure for this sale can be found here. 0.05% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC acquired a new position in Baxter International in the 3rd quarter valued at about $175,000. Americafirst Capital Management LLC acquired a new position in Baxter International in the 3rd quarter valued at about $710,000. Cypress Capital Group raised its stake in Baxter International by 65.8% in the 3rd quarter. Cypress Capital Group now owns 5,804 shares of the medical instruments supplier’s stock valued at $364,000 after purchasing an additional 2,304 shares during the last quarter. Stonebridge Capital Advisors LLC acquired a new position in Baxter International in the 3rd quarter valued at about $204,000. Finally, Colony Group LLC acquired a new position in Baxter International in the 3rd quarter valued at about $6,966,000. Institutional investors and hedge funds own 83.49% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/royal-bank-of-canada-reaffirms-hold-rating-for-baxter-international-inc-bax/1725056.html.

About Baxter International

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Analyst Recommendations for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.